FDA Pauses Eli Lilly Alzheimer's Drug Approval, Citing Safety Concerns
• FDA delayed decision on Eli Lilly's Alzheimer's drug donanemab, convening last-minute meeting to review trial data • Timing of FDA meeting and decision unclear, originally expected by end of February • Concerns center around safety, especially brain swelling and bleeding, of donanemab • Eli Lilly remains confident in donanemab, eager to present trial data and answer FDA questions • Eli Lilly stock dropped over 3% on Friday afternoon on news of FDA delay